Wednesday, 20 Mar 2019

Drug Safety

Datesort ascending Type Title Save
24 Sep 2018 Social Annals Int Med - analysis of adults prescribed opioids between 2006-2015 shows 31943 Rx visits for opioids - 5% for cancer pain, 66% for noncancer pain & 28.5% an Opioid was Rx without a pain Dx. https://t.co/6vKQbwEdkR
24 Sep 2018 Social Useful listing of Pregnancy Registries for drug info during pregnancy with arthritis, lupus and many other disorders including Mother to Baby, Pregnancy in FM, MS, OP, Breast cancer etc. https://t.co/sPETyaH9jX
18 Sep 2018 Social Open study of adalimumab and infliximab in recalcitrant (RV) retinal vasculitis (unresponsive to other therapies) - 48 pts Rx (1/2 ADA, 1/2 INFL) - RV remission within 54% @3 mos and 86% @ 12 mos. with no added benefit to other cotherapies. https://t.co/EvbFj6vXly
17 Sep 2018 Social NSAID-exacerbated respiratory disease occurs in 1/10 pts with asthma and rhinosinusitis- There are new expert guidelines on recognition, management, high morbidity and mortality risks. https://t.co/kY1RYSizqz
17 Sep 2018 Social Metanalysis of NSAID effects on CV risk (CVR) shows an overall, significant increased CVR (RR 1.24), especially for vascular events. Moreso for coxibs (RR 1.22) vs nonselective NSAIDs (1.18). CVR highest w/ rofecoxib (RR 1.39), then diclofenac & etoricoxib https://t.co/8LEDxYFTK4
14 Sep 2018 Social Correction 42%; Systemic onset JIA patients may have higher Injection Site Reaction rates when taking sc tocilizumab (42% sJIA) compared to polyarticular JIA (15-29%). RA ( 7-10%) or GCA https://t.co/ooDo1LjGlA
08 Sep 2018 Social RheumNow Week in Review is up! This week the sunshine folder & ugly tie rack! Watch the video here https://t.co/Lb0mFGPTHc or try the podcast on iTunes in your car or on Android Auto in your car on Stitcher or https://t.co/Lb0mFGPTHc
31 Aug 2018 News New BSR Guidelines on Biologic Safe Use with Inflammatory Arthritis
28 Aug 2018 News The Safety of Paternal Exposure to DMARDs and Biologics
27 Aug 2018 News 2018-2019 ACIP Recommendations for Seasonal Influenza Vaccination
27 Aug 2018 Social FDA no longer labels drugs for pregnancy as A, B, C, D, X. New PLLR rule of 2015 - says pregnancy info includes more written data, from human studies, registries, less animal data. This review article looks a the history and what the new labeling entails https://t.co/0nWInWO1A4
27 Aug 2018 Social FDA info on insulin use during disaster/hurricaine applies well to biologic use - "...that insulin be stored...~36°F to 46°F" until use... but "may be left unrefrigerated at 59°F to 86°F for up to 28 days and continue to work" Avoid extremes in temp! https://t.co/gyxbhDdxVt
26 Aug 2018 Slide of the day Avoiding Teratogens in Pregnancy
25 Aug 2018 Social @CCalabreseDO @HealioRheum I STRONGLY disagree. The FDA, CDC and ETN, ADA & Infliximab worked this out long ago with Package insert language for LTBI saying "anti-TB therapy must be started BEFORE the TNF inhibitor" Specifically they meant give 300 mg INH, then give TNFi. "2-8wks" has no scientific basis
25 Aug 2018 Social @RajkiranDudam @psufka @PatelAarat @RheumRegistrar @RheumJC @shikhsingla @rajsengupta @MedReuma Easy. Lower MTX dose. Folate every day may help. In my experience vitamin A 8000 IU qd helps w/ nausea and oral ulcers much moreso than playing with folate use. https://t.co/Lryb3KAaWC
24 Aug 2018 Social RT @RheumNow: Which Anti-Rheumatic is shown/known to be a clear teratogen and thus pregnancy must be prevented/avoided when taking this dru…
23 Aug 2018 Social Which Anti-Rheumatic is shown/known to be a clear teratogen and thus pregnancy must be prevented/avoided when taking this drug?
22 Aug 2018 Social Systematic review show that adherence and persistence on etanercept and adalimumab are quite low, often 50% or less, somewhat better w/ infliximab. How to improve? Supervised injectables or infusions, pt education, drug levels? https://t.co/7tP8zmDr4R
20 Aug 2018 News Health Secretary Azar Eyes Rebate Reform
06 Aug 2018 Social MAINRITSAN2 compared fixed dose (q 6 mos) RTX to "tailored" RTX (to CD19, ANCA titers) in 162 AAV (GPA, MPA) pts - BVAS/relapse rates similar betw fixed (17%) vs tailored (10%) (p=0.22) w/ less infusions in the latter (248 vs 381). https://t.co/swFosJvgGp